Lung Cancer Clinical Trial

A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

Summary

This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically or cytologically confirmed locally advanced or metastatic NSCLC, urothelial carcinoma or HNSCC
Progressed after at least 1 line of treatment and no more than 3 lines of treatment
At least one measurable lesion as defined by RECIST version 1.1
ECOG Performance Status 0 or 1
Adequate Bone Marrow Function
Adequate Renal Function
Adequate Liver Function
Resolved acute effects of any prior therapy

Exclusion Criteria:

Known active uncontrolled or symptomatic CNS metastases.
Major surgery, radiation therapy, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry.
Active, uncontrolled infection, including COVID-19
Known or suspected hypersensitivity to PF-06939999
Inability to consume or absorb study drug

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

54

Study ID:

NCT03854227

Recruitment Status:

Terminated

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 14 Locations for this study

See Locations Near You

Scottsdale Healthcare Hospitals d/b/a HonorHealth
Scottsdale Arizona, 85258, United States
Virginia G. Piper Cancer Pharmacy
Scottsdale Arizona, 85258, United States
Keck Hospital of USC
Los Angeles California, 90033, United States
LAC + USC Medical Center
Los Angeles California, 90033, United States
USC Norris Comprehensive Cancer Center
Los Angeles California, 90033, United States
USC/Norris Comprehensive Cancer Center
Los Angeles California, 90033, United States
Keck Medical Center of USC Pasadena
Pasadena California, 91105, United States
AdventHealth Celebration Infusion Center
Celebration Florida, 34747, United States
AdventHealth Medical Group Oncology Research at Celebration
Celebration Florida, 34747, United States
University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center
Miami Florida, 33136, United States
AdventHealth Hematology and Oncology
Orlando Florida, 32804, United States
AdventHealth Orlando - Investigational Drug Services
Orlando Florida, 32804, United States
AdventHealth Orlando Infusion Center
Orlando Florida, 32804, United States
St. Joseph Mercy Hospital
Ann Arbor Michigan, 48106, United States
St. Joseph Mercy Brighton
Brighton Michigan, 48114, United States
Henry-Joyce Cancer Clinic
Nashville Tennessee, 37232, United States
Oncology IDS Pharmacy
Nashville Tennessee, 37232, United States
The University of Texas
Houston Texas, 77030, United States
NEXT Oncology
San Antonio Texas, 78229, United States
Inova Schar Cancer Institute
Fairfax Virginia, 22031, United States
Seattle Cancer Care Alliance
Seattle Washington, 98109, United States
University of Washington Medical Center
Seattle Washington, 98195, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

54

Study ID:

NCT03854227

Recruitment Status:

Terminated

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.